Sustainability Report 2012 Lek d.d.

51 Labor / Products Graph 13: Training in 2012 by area (participation rate) 0.5% 0.4% 0.5% 23.8% 21.4% 39.2% 6.5% 7.8% Expert skills 39.2% Quality 23.8% Statutory skills 21.4% Development of communication skills 7.8% Governance and management 6.5% Foreign languages 0.5% Computer science and information technology 0.5% Marketing 0.4% 4. Products Lek provides the professional public in Slovenia with product information in accordance with marketing authorizations issu- ed by the Public Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP). Product-rela- ted communication with the professional public is based on Summary Product Characteristics approved by JAZMP and performed in accordance with the Medicinal Products Act. The key therapeutic groups of medicinal products developed, produced and marketed by Lek are listed under Item 1.3.2. Communication of information related to pharmaceuticals 70 is regulated by the Medicinal Products Act. Product-related information to the final consumer is provided in the form of patient information leaflets. With patient information leaflets, we openly and transparently communicate all the relevant information regarding the safety and efficacy of medicinal products, as well as posology and administrative information. Pursuant to the Novartis Policy, we communicate every infor- mation supported by reasonable scientific evidence, particu- larly those related to safety such as contraindications, warnin- gs, interactions etc. Similar practice applies to non-prescription drugs, where there is a growing need for clear and intelligible information. We ensure compliance with the Novartis Promotional Prac- tices Policy which, in several cases, is even more restrictive than the above Act. Every communication we provide to the professional public is supported by reasonable scientific evi- dence, particularly those related to safety such as contraindi- cations, warnings, interactions, etc. For non-prescription self-medication drugs, practice similar to that for prescription drugs applies. With patient information le- aflets, we openly and transparently communicate all the rele- vant information regarding the safety and efficacy of medicinal products, as well as posology and administrative information. In 2012, the use of non-prescription drugs recorded a decrea- se, which is the result of the overall economic situation and of the decline in our customers' purchasing power. In pharmacies and health institutions, various free health infor- mation materials are available for users of medicinal products, and medical advice can be obtained on our website at www.lek.si . Compliance with regulations concerning product infor- mation 71 In 2012, the Public Agency for Medicinal Products and Medi- cal Devices (JAZMP) initiated no offence procedure. Practices of measuring customer satisfaction 72 In 2012, no opinion survey about pharmaceutical compani- es was conducted. To gain an insight into the satisfaction of the professional public, a series of meetings were held. At workshops, we presented the company's achievements, and asked the professional public about their view of Lek, and their satisfaction with our interactions and prescription- and non-pre- scription drug portfolio. We asked for proposals for improve- ment. Once again, Lek proved to be enjoying a good reputation with the professional public which manifests a high degree of satisfaction with our product range. Programs for adherence to laws, standards, and volun- tary codes related to marketing communications, inclu- ding advertising, promotion, and sponsorship 73 In the field of drug advertising, we act in accordance with the Rules onAdvertising of Medicines (OG., RS105/ 2008, 105/ 2010, consolidated text, effective from 8 January 2011) and with the internal Promotional Practices Policy. Conformity of conduct is verified on a daily basis by previous approval of all promo- tional activities. Adherence to laws, standards, and voluntary codes re- lated to marketing communications, including adverti- sing, promotion, and sponsorship 74 In 2012, there were no cases of violations of marketing com- munication rules, standards and non-binding codes, including those related to advertising, promotion and sponsorship. The JAZMP instituted no procedures for any drug advertising in vio- lation of the Promotional Practices Rules. There was no spon- sorship involving drug promotion. In corporate sponsorship, there were no non-compliance cases. 70 GRI Indicator PR3 71 GRI Indicator PR4 72 GRI Indicator PR5 – partlially 73 GRI Indicator PR6 74 GRI Indicator PR7